title: BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines.
authors.forename: Katrin
authors.initials: K
authors.lastname: Ullrich
authors.forename: Kathrin D
authors.initials: KD
authors.lastname: Wurster
authors.forename: Björn
authors.initials: B
authors.lastname: Lamprecht
authors.forename: Karl
authors.initials: K
authors.lastname: Köchert
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Bernd
authors.initials: B
authors.lastname: Dörken
authors.forename: Martin
authors.initials: M
authors.lastname: Janz
authors.forename: Stephan
authors.initials: S
authors.lastname: Mathas
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001557:Benzenesulfonates / Q000494:pharmacology*; D045744:Cell Line, Tumor; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000494:pharmacology*; D016186:Receptor, Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D016186:Receptor, Macrophage Colony-Stimulating Factor